Review summary
Historical dates
January 30, 1882 – April 12, 1945Synthetic DOB
1964-01-30Index visit
2026-03-27 at age 62Synthetic MRN
HR-ET002-SYNTeaching objective: Diagnose and treat hypertensive heart failure with reduced ejection fraction using guideline-directed medical therapy, laboratory safety monitoring on the CMID schedule, iron repletion, and tobacco cessation, in a patient who uses a wheelchair, while keeping the contested cause of his 1921 paralysis out of the active diagnosis.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| January 30, 1882 | Born at Springwood in Hyde Park, New York. | CLM-0001 |
| 1900 | Father died during his first term at Harvard. | CLM-0009 |
| August 25, 1921 | Paralytic illness diagnosed as infantile paralysis; paraplegic thereafter. | CLM-0003, CLM-0004 |
| May 1941 | Severe iron deficiency anemia. | CLM-0005 |
| September 1941 | Mother died at Springwood. | CLM-0009 |
| March 27, 1944 | Examined at Bethesda Naval Hospital: hypertension, enlarged heart, and congestive heart failure. | CLM-0006, CLM-0007 |
| February 1945 | Blood pressure reported up to 260/150. | CLM-0008 |
| April 12, 1945 | Died of a cerebral hemorrhage at Warm Springs, Georgia. | CLM-0002, CLM-0008 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Franklin Delano Roosevelt was born on January 30, 1882, at Springwood, the family's estate in Hyde Park, New York. | confirmed | Springwood: Birthplace and Home to Franklin D. Roosevelt (Teaching with Historic Places) supports |
| D | Roosevelt died of a cerebral hemorrhage at Warm Springs, Georgia, on April 12, 1945, aged 63. Record the death as a fact without graphic detail. |
confirmed | Springwood: Birthplace and Home to Franklin D. Roosevelt (Teaching with Historic Places) supports The Dying President supports |
| D | In the summer of 1921 Roosevelt developed a paralytic illness at Campobello; on August 25, 1921, Dr. Robert Lovett diagnosed infantile paralysis (polio), and Roosevelt remained paraplegic, using leg braces from early 1922. The contemporaneous diagnosis was polio; a later retrospective analysis proposes another cause. |
confirmed | FDR and Polio supports Springwood: Birthplace and Home to Franklin D. Roosevelt (Teaching with Historic Places) supports |
| R | A 2003 Bayesian analysis of the recorded symptoms concluded that Guillain-Barré syndrome was more probable than paralytic polio as the cause of Roosevelt's 1921 illness; the conclusion is disputed and cannot be confirmed because no cerebrospinal fluid was examined. Keep the cause contested; the modern problem list records sequelae of the documented 1921 diagnosis. |
disputed | Goldman AS, Schmalstieg EJ, Freeman DH Jr, Goldman DA, Schmalstieg FC Jr. What was the cause of Franklin Delano Roosevelt's paralytic illness? J Med Biogr. 2003;11(4):232-240 supports |
| D | In May 1941 Roosevelt had severe iron deficiency anemia, with hemoglobin reported at 4.5 g/100 mL. Reported in a secondary medical account; the primary record was not reviewed. |
probable | Susmano A. Franklin Delano Roosevelt's last illness. Hektoen International. Spring 2012 supports |
| D | At an examination at Bethesda Naval Hospital on March 27, 1944, Roosevelt's blood pressure was 186/108; he was breathless and cyanotic with rales, and X-rays and an electrocardiogram showed an enlarged heart, congestive heart failure, and a mitral murmur. His blood pressure had not been checked since February 27, 1941. The documented anchor for the synthetic hypertensive heart failure episode. |
confirmed | The Dying President supports Susmano A. Franklin Delano Roosevelt's last illness. Hektoen International. Spring 2012 supports FDR: Secret Illness collection guide (citing Bruenn HG. Clinical notes on the illness and death of President Franklin D. Roosevelt. Ann Intern Med. 1970;72(4):579-591) context |
| D | After the March 1944 examination Roosevelt was treated with digitalis, a low-sodium and weight-reduction diet, and rest; his working hours were reduced, his cigarettes were limited to ten a day, and his evening cocktails were reduced. Documents tobacco use and the era's limited treatment options; no antihypertensive drugs were available. |
confirmed | The Dying President supports Susmano A. Franklin Delano Roosevelt's last illness. Hektoen International. Spring 2012 supports |
| D | Roosevelt's blood pressure remained severely elevated, reported up to 260/150 in February 1945 and ranging from 170/88 to 240/130 at Warm Springs before his death. | confirmed | Susmano A. Franklin Delano Roosevelt's last illness. Hektoen International. Spring 2012 supports The Dying President supports |
| D | Roosevelt's father, James Roosevelt, died in 1900 during Franklin's first term at Harvard; his mother, Sara Delano Roosevelt, died at Springwood in September 1941. The cited source does not give causes of death. |
confirmed | Springwood: Birthplace and Home to Franklin D. Roosevelt (Teaching with Historic Places) supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Hypertensive heart disease with heart failure; synthetic modern diagnosis linked to the documented 1944 findings | active | confirmed | both_with_link | CLM-0006, CLM-0008 |
| S | Heart failure with reduced ejection fraction, NYHA class III at diagnosis | active | confirmed | both_with_link | CLM-0006 |
| S | Nicotine dependence, cigarettes | active | confirmed | active | CLM-0007 |
| S | Iron deficiency anemia in heart failure, repleted with intravenous iron | resolved | confirmed | active | CLM-0005 |
| S | Paraplegia from a paralytic illness at age 39, historically diagnosed as poliomyelitis; cause retrospectively disputed | active | provisional | both_with_link | CLM-0003, CLM-0004 |
| S | Prediabetes | active | confirmed | active | |
| S | Hyperlipidemia | active | confirmed | active | |
| S | Acute viral gastroenteritis with mild volume depletion, resolved with oral rehydration and a short hold of heart failure medicines | resolved | confirmed | active |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-03-27 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 2850 pg/mL (high) Reference <=125 pg/mL |
http://loinc.org · 33762-6 |
| S | 2026-03-27 | Sodium [Moles/volume] in Serum or Plasma | 137 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-03-27 | Potassium [Moles/volume] in Serum or Plasma | 4.2 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-03-27 | Creatinine [Mass/volume] in Serum or Plasma | 1.18 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-03-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 70 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-03-27 | Glucose [Mass/volume] in Serum or Plasma | 104 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-03-27 | Hemoglobin [Mass/volume] in Blood | 12.6 g/dL (low) Reference 13.2-16.6 g/dL |
http://loinc.org · 718-7 |
| S | 2026-03-27 | Ferritin [Mass/volume] in Serum or Plasma | 48 ng/mL Reference 30-400 ng/mL |
http://loinc.org · 2276-4 |
| S | 2026-03-27 | Iron saturation [Mass Fraction] in Serum or Plasma | 16% (low) Reference 20-50% |
http://loinc.org · 2502-3 |
| S | 2026-03-27 | Thyrotropin [Units/volume] in Serum or Plasma | 2.1 mIU/L Reference 0.45-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-03-27 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 132 mg/dL (high) Reference <=99 mg/dL |
http://loinc.org · 13457-7 |
| S | 2026-03-27 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.9% (high) Reference <=5.6% |
http://loinc.org · 4548-4 |
| S | 2026-03-27 | Albumin/Creatinine [Mass Ratio] in Urine | 64 mg/g (high) Reference <=30 mg/g |
http://loinc.org · 9318-7 |
| S | 2026-03-27 | Overall summary score [KCCQ-12] | 38 | http://loinc.org · 86924-8 |
| S | 2026-03-27 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 2026-04-10 | Sodium [Moles/volume] in Serum or Plasma | 136 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-04-10 | Potassium [Moles/volume] in Serum or Plasma | 4.8 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-04-10 | Creatinine [Mass/volume] in Serum or Plasma | 1.29 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-04-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 63 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-04-10 | Glucose [Mass/volume] in Serum or Plasma | 98 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-04-10 | Left ventricular Ejection fraction | 30% (low) Reference 50-70% |
http://loinc.org · 10230-1 |
| S | 2026-06-26 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 980 pg/mL (high) Reference <=125 pg/mL |
http://loinc.org · 33762-6 |
| S | 2026-06-26 | Sodium [Moles/volume] in Serum or Plasma | 138 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-06-26 | Potassium [Moles/volume] in Serum or Plasma | 4.6 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-06-26 | Creatinine [Mass/volume] in Serum or Plasma | 1.24 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-06-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 66 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-06-26 | Glucose [Mass/volume] in Serum or Plasma | 96 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-06-26 | Hemoglobin [Mass/volume] in Blood | 13.6 g/dL Reference 13.2-16.6 g/dL |
http://loinc.org · 718-7 |
| S | 2026-06-26 | Ferritin [Mass/volume] in Serum or Plasma | 236 ng/mL Reference 30-400 ng/mL |
http://loinc.org · 2276-4 |
| S | 2026-06-26 | Iron saturation [Mass Fraction] in Serum or Plasma | 27% Reference 20-50% |
http://loinc.org · 2502-3 |
| S | 2026-06-26 | Overall summary score [KCCQ-12] | 64 | http://loinc.org · 86924-8 |
| S | 2026-06-26 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 2026-09-25 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 410 pg/mL (high) Reference <=125 pg/mL |
http://loinc.org · 33762-6 |
| S | 2026-09-25 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-09-25 | Potassium [Moles/volume] in Serum or Plasma | 4.5 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-09-25 | Creatinine [Mass/volume] in Serum or Plasma | 1.21 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-09-25 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 68 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-09-25 | Glucose [Mass/volume] in Serum or Plasma | 95 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-09-25 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 68 mg/dL Reference <=99 mg/dL |
http://loinc.org · 13457-7 |
| S | 2026-09-25 | Albumin/Creatinine [Mass Ratio] in Urine | 22 mg/g Reference <=30 mg/g |
http://loinc.org · 9318-7 |
| S | 2026-09-25 | Left ventricular Ejection fraction | 45% (low) Reference 50-70% |
http://loinc.org · 10230-1 |
| S | 2026-09-25 | Overall summary score [KCCQ-12] | 78 | http://loinc.org · 86924-8 |
| S | 2026-07-27 | Sodium [Moles/volume] in Serum or Plasma | 135 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-07-27 | Potassium [Moles/volume] in Serum or Plasma | 4.9 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-07-27 | Creatinine [Mass/volume] in Serum or Plasma | 1.42 mg/dL (high) Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-07-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 56 mL/min/1.73 m² (low) Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-07-27 | Glucose [Mass/volume] in Serum or Plasma | 92 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-10-23 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 2026-10-23 | Total score [AUDIT-C] | 2 | http://loinc.org · 75626-2 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-03-27 | Body height | 188 cm | 8302-2 | S |
| 2026-03-27 | Body weight | 88 kg | 29463-7 | S |
| 2026-03-27 | Body mass index (BMI) [Ratio] | 24.9 kg/m2 | 39156-5 | S |
| 2026-03-27 | Systolic blood pressure | 186 mm[Hg] | 8480-6 | S |
| 2026-03-27 | Diastolic blood pressure | 108 mm[Hg] | 8462-4 | S |
| 2026-03-27 | Heart rate | 96 /min | 8867-4 | S |
| 2026-03-27 | Respiratory rate | 22 /min | 9279-1 | S |
| 2026-03-27 | Body temperature | 36.9 Cel | 8310-5 | S |
| 2026-03-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 93 % | 59408-5 | S |
| 2026-04-10 | Body height | 188 cm | 8302-2 | S |
| 2026-04-10 | Body weight | 85 kg | 29463-7 | S |
| 2026-04-10 | Body mass index (BMI) [Ratio] | 24 kg/m2 | 39156-5 | S |
| 2026-04-10 | Systolic blood pressure | 148 mm[Hg] | 8480-6 | S |
| 2026-04-10 | Diastolic blood pressure | 88 mm[Hg] | 8462-4 | S |
| 2026-04-10 | Heart rate | 84 /min | 8867-4 | S |
| 2026-04-10 | Respiratory rate | 18 /min | 9279-1 | S |
| 2026-04-10 | Body temperature | 36.8 Cel | 8310-5 | S |
| 2026-04-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 % | 59408-5 | S |
| 2026-06-26 | Body height | 188 cm | 8302-2 | S |
| 2026-06-26 | Body weight | 83 kg | 29463-7 | S |
| 2026-06-26 | Body mass index (BMI) [Ratio] | 23.5 kg/m2 | 39156-5 | S |
| 2026-06-26 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2026-06-26 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-06-26 | Heart rate | 70 /min | 8867-4 | S |
| 2026-06-26 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-06-26 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-06-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-09-25 | Body height | 188 cm | 8302-2 | S |
| 2026-09-25 | Body weight | 82 kg | 29463-7 | S |
| 2026-09-25 | Body mass index (BMI) [Ratio] | 23.2 kg/m2 | 39156-5 | S |
| 2026-09-25 | Systolic blood pressure | 122 mm[Hg] | 8480-6 | S |
| 2026-09-25 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-09-25 | Heart rate | 64 /min | 8867-4 | S |
| 2026-09-25 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-09-25 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-09-25 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-07-27 | Body height | 188 cm | 8302-2 | S |
| 2026-07-27 | Body weight | 80.6 kg | 29463-7 | S |
| 2026-07-27 | Body mass index (BMI) [Ratio] | 22.8 kg/m2 | 39156-5 | S |
| 2026-07-27 | Systolic blood pressure | 102 mm[Hg] | 8480-6 | S |
| 2026-07-27 | Diastolic blood pressure | 64 mm[Hg] | 8462-4 | S |
| 2026-07-27 | Heart rate | 86 /min | 8867-4 | S |
| 2026-07-27 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-07-27 | Body temperature | 37.6 Cel | 8310-5 | S |
| 2026-07-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-10-23 | Body height | 188 cm | 8302-2 | S |
| 2026-10-23 | Body weight | 82 kg | 29463-7 | S |
| 2026-10-23 | Body mass index (BMI) [Ratio] | 23.2 kg/m2 | 39156-5 | S |
| 2026-10-23 | Systolic blood pressure | 120 mm[Hg] | 8480-6 | S |
| 2026-10-23 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 2026-10-23 | Heart rate | 62 /min | 8867-4 | S |
| 2026-10-23 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-10-23 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-10-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Current tobacco use: cigarettes, about one pack a day for more than thirty years at intake; abstinent since April 2026
- S Current alcohol use: one or two cocktails most evenings, reduced to occasional use
- S Occupation: elected public official with long workdays and frequent travel
- S Supports: spouse, an adult daughter who encouraged this visit, and close staff
Functional status
- S Uses a manual wheelchair since a paralytic illness at age 39; independent in transfers and upper-body activities of daily living
- S Breathless after propelling the wheelchair short distances and when lying flat; NYHA class III at intake
Mental status
- S Alert, fully oriented, and good-humored; tends to minimize symptoms
- S Mood euthymic; PHQ-2 negative
Allergies and medications
Allergies
- S No known allergy
Medications
- S Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet by mouth twice daily
- S Sacubitril 49 mg / valsartan 51 mg oral tablet, one tablet by mouth twice daily
- S Carvedilol 3.125 mg oral tablet, one tablet by mouth twice daily with food
- S Carvedilol 6.25 mg oral tablet, one tablet by mouth twice daily with food
- S Carvedilol 12.5 mg oral tablet, one tablet by mouth twice daily with food
- S Spironolactone 25 mg oral tablet, one tablet by mouth daily
- S Empagliflozin 10 mg oral tablet, one tablet by mouth daily
- S Furosemide 20 mg oral tablet, one tablet by mouth daily
- S Atorvastatin 40 mg oral tablet, one tablet by mouth daily
- S Nicotine 21 mg/24 hr transdermal patch, apply one patch daily
- S Ferric carboxymaltose 750 mg in 15 mL intravenous infusion, two doses one week apart
Procedures and immunizations
Procedures
- S Transthoracic echocardiography
- S Transthoracic echocardiography
Immunizations
- S 2025-10-14: Influenza vaccine, 2025-2026 season
- S 2026-04-10: Pneumococcal conjugate vaccine PCV20
- S 2021-05-03: Tdap vaccine
- S 2026-10-23: Influenza vaccine, 2026-2027 season
- S 2026-10-23: Recombinant zoster vaccine, dose 1 of 2
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D August 25, 1921: Paralytic illness in August 1921, diagnosed at the time as infantile paralysis (polio); paraplegic thereafter, with leg braces from early 1922 (CLM-0003)
- R Proposed in 2003 about the 1921 illness: Guillain-Barré syndrome proposed retrospectively as the cause of the 1921 paralysis; disputed (CLM-0004)
- D May 1941: Severe iron deficiency anemia in May 1941, hemoglobin reported at 4.5 g/100 mL (CLM-0005)
Family history
- D father: Died in 1900; cause not recorded in the cited source
- D mother: Died in September 1941; cause not recorded in the cited source
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Lower blood pressure below 130/80 by the six-month review | 2026-09-25 | completed | Blood pressure 122/76 |
| Improve the KCCQ-12 overall summary score by at least 20 points by the three-month review | 2026-06-26 | completed | KCCQ-12 rose from 38 to 64 |
| Stop smoking by the three-month review | 2026-06-26 | completed | No cigarettes since April; nicotine patch course completed |
| Reach the highest tolerated doses of guideline-directed therapy by the six-month review | 2026-09-25 | completed | Sacubitril/valsartan 49/51 mg twice daily, carvedilol 12.5 mg twice daily, spironolactone, and empagliflozin |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Start guideline-directed therapy for HFrEF: sacubitril/valsartan, carvedilol, and empagliflozin, with furosemide for congestion; add spironolactone after the two-week potassium check | completed | GL-HF-2022 |
| Check a basic metabolic panel one to two weeks after each renin-angiotensin or mineralocorticoid antagonist change, then every three to six months when stable | completed | GL-CMID-2026, GL-HF-2022 |
| Treat to a blood pressure below 130/80 with home blood pressure and daily weight logs; low-sodium diet | completed | GL-HTN-2025, GL-CMID-2026 |
| Give intravenous ferric carboxymaltose for iron deficiency with ferritin below 100 ng/mL and transferrin saturation below 20% | completed | GL-HF-2022 |
| Tobacco cessation counseling with nicotine replacement and a quit date | completed | GL-TOBACCO-2021 |
| Cardiology referral to confirm the diagnosis, review the echocardiogram, and guide titration | completed | GL-HF-2022 |
| Repeat echocardiogram three to six months after reaching tolerated doses to decide on device therapy | completed | GL-HF-2022, GL-CMID-2026 |
Planned encounters
- 2026-03-27 — Primary care visit for breathlessness, orthopnea, and leg swelling (ENC-001)
- 2026-04-10 — Two-week heart failure medication safety check and echocardiogram (ENC-002)
- 2026-06-26 — Three-month heart failure and blood pressure review (ENC-003)
- 2026-07-27 — Same-day sick visit for vomiting and diarrhea (ENC-005, unscheduled)
- 2026-09-25 — Six-month heart failure review with repeat echocardiogram (ENC-004)
- 2026-10-23 — Periodic adult preventive visit (ENC-006)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Sick Visit
- Progress note 05 — Focused Visit (Care-plan review)
- Progress note 06 — Preventive Visit
- Cardiology referral
- Cardiology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Sick Visit (XML)
- Progress note 05 — Focused Visit (Care-plan review) (XML)
- Progress note 06 — Preventive Visit (XML)
- Cardiology referral (XML)
- Cardiology consultation (XML)
Sources
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review. |
| provenance review | not_started | NPS, FDR Library, and PubMed abstract logged; Bruenn's 1970 article not reviewed in full. |
| safe messaging review | not_started | No behavioral-health content; death recorded without graphic detail. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.